Asano et al. showed that intestinal CD169+ macrophage-derived CCL8 functioned as a stimulant for the breakdown of barrier defense in experimentally induced colitis in mice, and anti-CCL8 neutralizing antibody was a promising target for the suppression of mucosal damage and clinical symptoms of experimentally induced colitis. The gene discussed is SIGLEC1; the disease is colitis.